CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 76 enrolled
Drug / intervention
Testosterone Solution 2% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01419236
NCT01419236Phase 2Completed

A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Explore the Impact of Testosterone Solution 2% on Symptoms of Ejaculatory Dysfunction in Men With Testosterone Deficiency

Eli Lilly and Company·interventional·Posted Aug 18, 2011·Updated Dec 19, 2014

In Brief

A Phase 2 clinical trial evaluating Testosterone Solution 2% and Placebo Solution for Ejaculatory Dysfunction and Hypogonadism. Completed, enrolled 76 participants across 7 sites in 2 countries.

Detailed Summary

The purpose of this study is to see if testosterone solution 2% can impact symptoms of ejaculatory dysfunction in men with low testosterone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 18, 2011
Enrollment StartAug 1, 2011
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.9 years ago

Interventions

Testosterone Solution 2%drug

Administered topically

Placebo Solutiondrug

Administered topically